2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-32329R
    Setiptiline (Standard) 57262-94-9
    Setiptiline (Standard) is the analytical standard of Setiptiline. This product is intended for research and analytical applications. Setiptiline (Org-8282) is a serotonin receptor antagonist. Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). Setiptiline acts as a norepinephrine reuptake inhibitor, α2-adrenergic receptor antagonist, and serotonin receptor antagonist, likely at the 5-HT2A, 5-HT2C, and/or 5-HT3 subtypes, as well as an H1 receptor inverse agonist/antihistamine.
    Setiptiline (Standard)
  • HY-32329S
    Setiptiline-d3 1795024-97-3 98%
    Setiptiline-d3 is the deuterium labeled Setiptiline. Setiptiline (Org-8282) is a serotonin receptor antagonist. Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). Setiptiline acts as a norepinephrine reuptake inhibitor, α2-adrenergic receptor antagonist, and serotonin receptor antagonist, likely at the 5-HT2A, 5-HT2C, and/or 5-HT3 subtypes, as well as an H1 receptor inverse agonist/antihistamine.
    Setiptiline-d3
  • HY-32709S
    Telcagepant-d8 1132641-75-8 98%
    Telcagepant-d8 (MK-0974-d8) is deuterium labeled Telcagepant. Telcagepant (MK-0974) is an orally active calcitonin gene-related peptide (CGRP) receptor antagonist with Kis of 0.77 nM and 1.2 nM for human and rhesus CGRP receptors, respectively.
    Telcagepant-d8
  • HY-33009R
    AS057278 (Standard) 402-61-9
    AS057278 (Standard) is the analytical standard of AS057278. This product is intended for research and analytical applications. AS057278 is a potent, selective, orally active and blood-brain barrier (BBB) penetrant non-peptidic D-amino acid oxidase (DAAO) inhibitor with an IC50 value of 0.91 μM and EC50 of 2.2-3.95 μM. AS057278 can normalize phencyclidine (PCP)-induced prepulse inhibition in mice. AS057278 can be used for researching schizophrenia.
    AS057278 (Standard)
  • HY-33549R
    α-Methyl-p-tyrosine (Standard) 658-48-0
    α-Methyl-p-tyrosine (Standard) is the analytical standard of α-Methyl-p-tyrosine. This product is intended for research and analytical applications. α-Methyl-p-tyrosine is a competitive inhibitor of tyrosine hydroxylase, which converts tyrosine into DOPA. α-Methyl-p-tyrosine is also an orally active inhibitor of catecholamine synthesis, inhibiting the hydroxylation of tyrosine into DOPA. α-Methyl-p-tyrosine can be used in research related to epilepsy, glaucoma, cancer, and other related diseases.
    α-Methyl-p-tyrosine (Standard)
  • HY-401563
    5-HT2A antagonist 4 methanesulfonate 676116-04-4 98%
    5-HT2A antagonist 4 methanesulfonate (Example 29) is a dopamine D2 receptor and serotonin 5HT2A receptor antagonist. 5-HT2A antagonist 4 methanesulfonate can be used for the study of central nervous system diseases.
    5-HT2A antagonist 4 methanesulfonate
  • HY-40294R
    Indazole (Standard) 271-44-3
    Indazole (Standard) is the analytical standard of Indazole. This product is intended for research and analytical applications. Indazole, also called isoindazole, a heterocyclic aromatic organic compound. Its derivatives display a broad variety of biological activities including anti-inflammatory, antibacterial, anti-HIV, antiarrhythmic, antifungal and antitumour properties. Indazole and its derivatives can be used for research of cancer, neurological disorders, cardiovascular diseases, gastrointestinal diseases.
    Indazole (Standard)
  • HY-50098R
    Mardepodect (Standard) 898562-94-2 98%
    Mardepodect (Standard) is the analytical standard of Mardepodect. This product is intended for research and analytical applications. Mardepodect (PF-2545920) is a potent, orally active and selective PDE10A inhibitor with an IC50 of 0.37 nM, with >1000-fold selectivity over other PDEs. Mardepodect can cross the blood-brain barrier.
    Mardepodect (Standard)
  • HY-50682A
    Azeliragon dihydrochloride 1284150-65-7 98%
    Azeliragon dihydrochloride (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD). Azeliragon dihydrochloride also can cross the blood-brain barrier (BBB).
    Azeliragon dihydrochloride
  • HY-50682R
    Azeliragon (Standard) 603148-36-3 98%
    Azeliragon (Standard) is the analytical standard of Azeliragon. This product is intended for research and analytical applications. Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD). Azeliragon also can cross the blood-brain barrier (BBB).
    Azeliragon (Standard)
  • HY-50722B
    NNC 55-0396 free base 357400-14-7 98%
    NNC 55-0396 free base is a blood-brain-barrier-permeable T-type Ca2+ channel inhibitor and pan-P450 inhibitor. NNC 55-0396 free base selectively inhibits T-type Ca2+ channels, suppresses HIF-1α expression and stability and inhibits Kv currents. NNC 55-0396 free base reduces brain infarct and attenuates neurological dysfunction. NNC 55-0396 free base inhibits the activity of multiple P450 enzymes. NNC 55-0396 (free base) can be used for the research of brain injury, hypertension, and glioblastoma.
    NNC 55-0396 free base
  • HY-50752A
    LY-411575 (isomer 1) 209984-58-7 99.51%
    LY-411575 isomer 1 is an isomer of LY411575, which is a potent γ-secretase inhibitor.
    LY-411575 (isomer 1)
  • HY-50752B
    LY-411575 (isomer 2) 2070009-70-8 99.84%
    LY-411575 isomer 2 is an isomer of LY411575, which is a potent γ-secretase inhibitor.
    LY-411575 (isomer 2)
  • HY-50752C
    LY-411575 (isomer 3) 2070009-28-6 99.27%
    LY-411575 isomer 3 is an isomer of LY411575, which is a potent γ-secretase inhibitor.
    LY-411575 (isomer 3)
  • HY-50882A
    ELN318463 racemate 851599-82-1 98%
    ELN318463 racemate is the racemate of ELN318463. ELN318463 is an amyloid precursor protein (APP) selective γ-secretase inhibitor. ELN318463 shows differential inhibition of presenilin (PS1)- and PS2-comprised γ-secretase with EC50s of 12nM and 656 nM for PS1and PS2, respectively. ELN318463 is 51-fold more selective for PS1.
    ELN318463 racemate
  • HY-59208R
    4-Quinolinol (Standard) 611-36-9 98%
    4-Quinolinol (Standard) is the analytical standard of 4-Quinolinol. This product is intended for research and analytical applications. 4-Quinolone (Kynurine) is a quinoline derivative. Kynurine pathway modulates tryptophan metabolism and involves in neuroprotective effect. Kynurine promotes tumor cell survival and motility by suppressing antitumor immune.
    4-Quinolinol (Standard)
  • HY-66012R
    Proparacaine hydrochloride (Standard) 5875-06-9 98%
    Proparacaine (Hydrochloride) (Standard) is the analytical standard of Proparacaine (Hydrochloride). This product is intended for research and analytical applications. Proparacaine hydrochloride is a local anesthetic. Proparacaine hydrochloride blocks voltage-gated sodium channels on neuronal cell membranes, thereby inhibiting signal conduction and nociceptive signal transmission. Proparacaine hydrochloride blocks nociceptive signals in the eye and induces ocular muscle relaxation to reduce eye movement during surgery. Proparacaine hydrochloride is used in research related to cataracts.
    Proparacaine hydrochloride (Standard)
  • HY-69359R
    Nipecotic acid (Standard) 498-95-3
    Nipecotic acid (Standard) is the analytical standard of Nipecotic acid. This product is intended for research and analytical applications. Nipecotic acid ((±)-β-Homoproline) is a potent inhibitor of neuronal and glial-aminobutyric acid (GABA) uptake in vitro. Nipecotic acid can also directly activate GABAA-like chloride channels, with an EC50 of approximately 300 μM.
    Nipecotic acid (Standard)
  • HY-70050B
    Alosetron ((Z)-2-butenedioate) 122852-43-1 98%
    Alosetron (GR 68755) (Z)-2-butenedioate is a potent and highly selective serotonin 5-HT3 receptor antagonist. Alosetron (Z)-2-butenedioate is used for the research of irritable bowel syndrome (IBS). Alosetron (Z)-2-butenedioate blocks the fast 5HT3-mediated depolarisation of guinea-pig myenteric and submucosal neurons, with IC50 at ~55 nM. Alosetron (Z)-2-butenedioate attenuates the visceral nociceptive effect of rectal distension in conscious or anaesthetised dogs. Anti-inflammatory effects.
    Alosetron ((Z)-2-butenedioate)
  • HY-70053S
    rac-Fesoterodine-d14 fumarate 1185237-08-4 98%
    (Rac)-Fesoterodine-d14 fumarate is a labelled racemic Fesoterodine. Fesoterodine is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKivalues of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine is used for the overactive bladder (OAB).
    rac-Fesoterodine-d14 fumarate
Cat. No. Product Name / Synonyms Application Reactivity